The review is careful to separate what is established from what remains hypothetical, a distinction that matters in a field where observational data can easily be overinterpreted. The authors distinguish three clinical scenarios that are often conflated in the literature. The first is simultaneous co-infection, in which a patient harbors both SARS-CoV-2 and actively toxin-producing C. difficile at the same time. The second is CDI that develops during hospitalization for COVID-19, a situation in which antimicrobial exposure and disrupted infection-prevention practices during pandemic surges may play dominant roles. The third, and perhaps the most intriguing, is delayed or recurrent CDI after apparent recovery from acute infection, which points toward persistent alterations of the intestinal ecosystem rather than simple nosocomial exposure. Each scenario implies a different balance of contributing causes, and each demands a different study design to disentangle.

The most straightforward explanation for an association between the two diseases is iatrogenic. Patients hospitalized with severe COVID-19 frequently received broad-spectrum antibiotics, either because bacterial co-infection was suspected or as empirical coverage during the chaotic early phases of the pandemic, when distinguishing viral pneumonia from secondary bacterial infection was difficult. Antibiotic exposure is the single strongest risk factor for C. difficile infection because it dismantles colonization resistance, the collective ability of a diverse gut microbiota to suppress pathogen expansion through competition for nutrients, production of bacteriocins, and, critically, the metabolism of bile acids. Primary bile acids such as taurocholate stimulate germination of C. difficile spores, while secondary bile acids generated by commensal bacteria inhibit its growth. When antibiotics deplete the bile acid-metabolizing community, the gut becomes a permissive niche for the pathogen.

Yet the review argues that antibiotics and hospitalization alone cannot fully account for the observed patterns. SARS-CoV-2 is increasingly recognized as an agent capable of perturbing the gut directly. Viral RNA has been detected in intestinal tissue and stool, and the angiotensin-converting enzyme 2 receptor, the cellular entry gate for the virus, is abundantly expressed on intestinal epithelial cells, particularly mature enterocytes of the small intestine. The authors emphasize that ACE2 is not merely a viral docking site. In normal physiology, ACE2 participates in regulating amino acid homeostasis, antimicrobial peptide expression, and the composition of the gut microbiome. Loss or dysregulation of ACE2 function during infection could therefore weaken epithelial barrier integrity and shift the microbial community toward a dysbiotic state, independently of any antimicrobial exposure.

This leads to the renin-angiotensin system, one of the review’s central mechanistic themes. SARS-CoV-2 binding to ACE2 promotes internalization and degradation of the receptor, reducing its protective enzymatic activity. The consequence is an imbalance in the renin-angiotensin axis: less angiotensin II is converted into the vasoprotective angiotensin-(1-7), and unopposed angiotensin II signaling through the AT1 receptor increases. In the intestine, excessive angiotensin II/AT1R signaling is associated with inflammation, increased epithelial permeability, and impaired barrier repair. The authors propose that this signaling imbalance could amplify mucosal damage during COVID-19 and thereby lower the threshold at which residual C. difficile spores, persisting in the lumen after germination conditions improve, can establish infection and produce toxin.

Downstream of angiotensin signaling, the review highlights inflammatory cascades that connect viral injury to bacterial opportunity. Severe COVID-19 is characterized by activation of the transcription factors NF-κB and MAPK in epithelial and immune cells, driving robust production of interleukin-6 and other pro-inflammatory mediators. Persistent inflammatory signaling can disrupt epithelial tight junctions, alter mucus production, and change the metabolic landscape of the lumen in ways that favor pathogenic taxa over obligate anaerobes that maintain colonization resistance. The authors also draw attention to nutritional vulnerability, noting that malnutrition and micronutrient deficiencies, common in hospitalized and older patients, impair epithelial regeneration and immune defense. They further discuss apolipoprotein E-related immunometabolic pathways as a possible link between host lipid metabolism, inflammatory resolution, and susceptibility to intestinal injury, an area they flag as requiring direct experimental validation.

Among the more forward-looking elements of the review is its treatment of extracellular vesicles as a potential biomarker framework. Extracellular vesicles, small membrane-bound particles released by cells into circulation and bodily fluids, carry proteins, lipids, and nucleic acids that reflect the physiological state of their cell of origin. The authors suggest that vesicle cargo could eventually serve as a readout of the combined inflammatory, epithelial, and microbial perturbations that characterize patients at heightened risk of CDI during or after COVID-19. Such biomarkers could, in principle, allow clinicians to identify which recovered COVID-19 patients warrant closer surveillance for delayed intestinal complications, although this remains a hypothesis-generating proposal rather than a validated clinical tool.

The authors are explicit that direct longitudinal evidence linking SARS-CoV-2 infection to subsequent CDI remains limited. Much of the available data come from single-center cohorts, retrospective chart reviews, and studies with heterogeneous testing practices, which complicates interpretation. Distinguishing true C. difficile infection from colonization in patients with diarrhea of other causes is a persistent diagnostic challenge, and pandemic-era disruptions to infection-prevention bundles and testing algorithms further muddy the picture. What the review offers instead is convergence: multiple independent lines of clinical and experimental evidence that all point in the same direction, supporting what the authors describe as a cautious, testable hypothesis rather than a demonstrated causal relationship.

To move the field forward, the review calls for prospective studies with standardized CDI testing protocols, careful quantification of antimicrobial exposure, and integrated microbiome and metabolomic profiling of patients followed from acute COVID-19 through recovery. Such studies would need to track bile acid pools, inflammatory markers, and microbial community structure over time to determine whether SARS-CoV-2 infection produces a durable shift in colonization resistance, and whether that shift translates into elevated risk of primary or recurrent CDI. Mechanistic biomarker discovery, including the extracellular vesicle framework, would ideally proceed in parallel. The authors also underline the importance of clarifying prognosis and long-term consequences, since recurrent CDI carries substantial morbidity and mortality in the same older and medically complex populations that bore the heaviest burden of the pandemic.

The broader significance of the work lies in its reframing of COVID-19 as a condition with potential gastrointestinal sequelae mediated through the microbiome, rather than a purely respiratory illness. If the hypothesis holds, the implications extend beyond the acute pandemic: clinicians managing patients recovering from severe COVID-19 may need to weigh antibiotic stewardship more carefully, monitor for gastrointestinal symptoms after discharge, and consider gut-protective strategies such as targeted microbiome restoration. At the same time, the review’s disciplined separation of established observations from mechanistic speculation serves as a model for how the field should proceed. The interaction between a global respiratory pathogen and an opportunistic intestinal spore-former is almost certainly multifactorial, involving antimicrobial exposure, hospitalization dynamics, dysbiosis, barrier dysfunction, altered bile acid metabolism, and persistent inflammation. Untangling those threads will require exactly the kind of rigorous, longitudinal, mechanistically informed research that the authors advocate.

Subject of Research: Potential mechanisms linking COVID-19 and Clostridioides difficile infection through gut dysbiosis

Article Title: COVID-19 and clostridioides difficile infection: clinical overlap, gut dysbiosis, and mechanistic hypotheses

Article References: de Carvalho Leitão, R. F., da Silva Costa, D. V., Nguyen, A., Vieira, L. L., Nunes, P. I. G., Warren, C. A., Oriá, R. B., & de Castro Brito, G. A. (2026). COVID-19 and clostridioides difficile infection: clinical overlap, gut dysbiosis, and mechanistic hypotheses. Gut Pathogens. https://doi.org/10.1186/s13099-026-00862-0

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00862-0

Keywords: COVID-19, Clostridioides difficile, SARS-CoV-2, ACE2, gut dysbiosis, renin-angiotensin system, bile acid metabolism, colonization resistance, inflammation, extracellular vesicles, hospitalization, antibiotic exposure

Primary biliary cholangitis, or PBC, is a chronic autoimmune condition in which the immune system slowly destroys the small bile ducts inside the liver. As bile accumulates and backs up, patients develop cholestatic liver injury, progressive scarring, and, in advanced cases, cirrhosis. The disease is strongly associated with anti-mitochondrial antibodies, particularly those targeting the pyruvate dehydrogenase complex component E2, yet the environmental triggers that set this autoimmune cascade in motion have remained frustratingly elusive. Genetic susceptibility accounts for only part of the story, and epidemiological studies have repeatedly pointed to gut microbes as potential culprits. What has been missing is a mechanistic account of how specific bacterial species might translate an altered gut community into immune attack on the bile ducts.

To close that gap, the research team established a mouse model in which healthy mice received fecal microbiota transplants from patients with PBC. The rationale was straightforward: if the gut community of PBC patients carries disease-promoting properties, transferring it into mice should reproduce at least some of the disease’s features. It did. Mice that received PBC-derived microbiota developed cholestatic liver injury, produced anti-mitochondrial antibodies, and showed pericholangitis, the inflammatory infiltration around bile ducts that defines the human disease. The researchers assessed liver damage through serological markers such as alanine aminotransferase and alkaline phosphatase, through histological examination, and through molecular assays, and found consistent evidence of hepatic inflammation in the transplanted animals.

Characterization of the gut microbiota by 16S rDNA sequencing revealed a community in disarray. Model mice showed a reduction in beneficial bacteria alongside an enrichment of potentially pathogenic organisms, including members of the genera Bacteroides and Aeromonas. Alongside these compositional shifts, the animals displayed measurable damage to the intestinal barrier, the single layer of epithelial cells and mucus that normally keeps the trillions of resident microbes safely compartmentalized within the gut lumen. Barrier integrity is a critical checkpoint in the gut-liver axis, because the liver receives the entire venous drainage of the intestine through the portal vein. When that barrier fails, microbial products and, as this study suggests, the microbes themselves gain direct access to hepatic tissue.

The pivotal discovery came when the team tracked Klebsiella pneumoniae specifically. Using bacterial culture, fluorescence in situ hybridization, and polymerase chain reaction, the researchers detected K. pneumoniae colonization in the livers of both the PBC-fecal-transplanted mice and, strikingly, in liver samples from patients with PBC. The abundance of the bacterium in the liver correlated positively with liver function indices, suggesting that the degree of bacterial translocation tracks with the severity of hepatic dysfunction. This is a significant observation because it moves K. pneumoniae from the category of a gut bystander, merely enriched in dysbiotic communities, to that of an invasive participant physically present at the site of tissue destruction.

To test whether the bacterium alone could drive the observed pathology, the investigators performed mono-colonization experiments, introducing K. pneumoniae into otherwise controlled animals. The results confirmed the bacterium’s pathogenic potential in this context: mono-colonized mice exhibited disruption of the intestinal barrier, translocation of the organism to the liver, liver injury, and disturbances in hepatic metabolic pathways. The bacterium, in other words, was sufficient to reproduce the core sequence of events seen in the fecal transplant model, from barrier breakdown to hepatic inflammation.

Transcriptomic analysis added a layer of molecular detail to the picture. RNA sequencing of liver tissue from the PBC-fecal-transplanted mice revealed significant activation of immune and inflammatory pathways alongside suppression of a broad range of metabolic pathways. Gene set enrichment analysis highlighted the scale of the transcriptional reprogramming, with differentially expressed genes clustering around inflammatory signaling while metabolic functions, including those related to bile acid handling, were dialed down. Because PBC is fundamentally a disease of bile flow, the suppression of bile acid metabolism by a translocated gut bacterium provides a plausible mechanism by which microbial invasion could accelerate the cholestatic process. The authors conclude that K. pneumoniae likely contributes to disease progression by impairing metabolic functions such as bile acid metabolism, in addition to stoking local inflammation.

The study also explored whether intervening on the microbial side could blunt the damage. When the researchers treated the PBC-fecal-transplanted mice with metronidazole, an antibiotic active against anaerobic and certain other bacteria, liver injury was partially alleviated, and some of the transcriptional pathways associated with K. pneumoniae were reversed. The partial nature of the rescue is itself informative. It suggests that while K. pneumoniae is an important driver, the dysbiotic community as a whole, including the enriched Bacteroides and Aeromonas populations and the broader loss of protective taxa, contributes to the disease phenotype. Antibiotic monotherapy, in this framing, is a blunt instrument that removes some offenders but does not restore the ecological balance of the gut.

Correlation analyses tying the microbial findings to clinical data strengthened the translational relevance of the work. Spearman correlation was used to evaluate relationships between microbiota composition and clinical parameters, and the hepatic transcriptome profiling linked the presence of translocated bacteria to specific gene expression signatures. The convergence of patient data and mouse experiments is what distinguishes this study from much of the correlative literature on the microbiome in liver disease. Rather than simply reporting that PBC patients have different gut communities, the team demonstrated that those communities can transfer disease traits, identified a specific translocating species, localized it in human and murine liver tissue, and showed that it is both sufficient to cause injury and partially targetable by an existing drug.

The implications reach beyond PBC. The gut-liver axis has been implicated in a widening range of conditions, from non-alcoholic steatohepatitis to alcoholic liver disease, and the methodological playbook used here, combining fecal microbiota transplantation, microbial tracking by culture and FISH, transcriptomics, and targeted intervention, offers a template for dissecting microbial contributions in other diseases. For PBC specifically, the findings raise the prospect of microbiome-directed therapies, whether through targeted antimicrobials, live biotherapeutics designed to restore barrier-protective taxa, or dietary and prebiotic strategies that suppress the expansion of translocation-competent pathogens. Considerable work remains before such approaches reach the clinic, including a fuller accounting of how K. pneumoniae crosses the epithelial barrier, how it survives hepatic immune defenses, and whether eliminating it alters the long-term course of the disease. But the study establishes a concrete, testable mechanism linking an altered gut ecosystem to autoimmune bile duct destruction, and it identifies a specific, cultivable bacterium as a promising therapeutic target in a disease that has long lacked one.

Subject of Research: The role of gut-derived Klebsiella pneumoniae translocation in driving hepatic inflammation in primary biliary cholangitis

Article Title: Gut-derived Klebsiella pneumoniae in primary biliary cholangitis patients translocates to liver and induces hepatic inflammation

Article References: Wang, X., Yang, H., Chu, H., Zhang, X., Li, J., Liu, M., Zhou, S., Yang, Z., Zhao, J., Wang, B., Ran, Y., Li, L., & Zhou, L. (2026). Gut-derived Klebsiella pneumoniae in primary biliary cholangitis patients translocates to liver and induces hepatic inflammation. Gut Pathogens. https://doi.org/10.1186/s13099-026-00880-y

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00880-y

Keywords: primary biliary cholangitis, Klebsiella pneumoniae, gut-liver axis, fecal microbiota transplantation, gut microbiota, bile acid metabolism, intestinal barrier, liver inflammation, metronidazole, RNA sequencing, autoimmune liver disease, microbiome

Diabetic kidney disease is the leading cause of end-stage renal disease worldwide, and it often progresses silently. By the time patients notice symptoms, significant nephron loss may already have occurred. Current diagnostic tools rely on the urinary albumin-to-creatinine ratio, which tracks protein leakage into the urine, and the estimated glomerular filtration rate, which measures how well the kidneys filter blood. Both markers are useful but imperfect, particularly in the earliest phase of injury when albumin excretion is just beginning to climb. The search for complementary biomarkers has therefore become a priority in nephrology and endocrinology alike, and bile acids have emerged as intriguing candidates because they are far more than digestive detergents.

Bile acids act as signaling molecules that engage receptors such as the farnesoid X receptor and TGR5, influencing glucose metabolism, lipid handling, inflammation, and even renal hemodynamics. Previous studies had hinted at altered bile acid profiles in diabetes and chronic kidney disease, but the dynamic trajectory of total bile acids across the successive stages of diabetic kidney disease remained unclear. To address this gap, Lei Xu, Bo Feng, and Xinfeng Yan conducted a retrospective cross-sectional study of 485 individuals whose clinical data were collected between August 2025 and February 2026 at Shanghai East Hospital, with ethics approval granted in April 2026 and a waiver of informed consent for the use of de-identified routine care records.

The study population was stratified into five groups: 87 people with normal glycemia, 126 with uncomplicated type 2 diabetes mellitus, and three groups of patients with diabetic kidney disease at stages 1, 2, and 3, comprising 118, 80, and 74 individuals respectively. Classification followed standard criteria based on the urinary albumin-to-creatinine ratio and estimated glomerular filtration rate, with diabetes diagnoses anchored to the 1999 World Health Organization standards. The researchers compared serum total bile acid concentrations across groups using non-parametric tests and then probed the shape of the relationship with polynomial regression, a statistical technique capable of detecting curved, rather than straight-line, patterns in data.

The results revealed a pronounced inverted U-shaped pattern that the authors confirmed statistically with a significant quadratic term, yielding a P value for non-linearity of 0.013. Total bile acid levels were modestly elevated in uncomplicated diabetes, with a median of 2.25 micromoles per liter, but jumped abruptly at stage 1 diabetic kidney disease, where the median reached 3.65 micromoles per liter, a difference highly significant against the uncomplicated diabetes group. By stage 3, the median had fallen to 1.95 micromoles per liter, dipping even below the level seen in diabetes without kidney complications. In other words, the bile acid surge is not a simple byproduct of declining renal function but appears concentrated in the early, potentially still reversible phase of injury.

To test whether this association stood on its own, the team built a multivariate logistic regression model adjusting for a long list of potential confounders, including age, diabetes duration, blood pressure, glycated hemoglobin, body mass index, lipid profiles, estimated glomerular filtration rate, fatty liver status, and the use of antidiabetic medications or statins. Even after these adjustments, total bile acid remained independently associated with early-stage diabetic kidney disease, with a fully adjusted odds ratio of 1.394 per unit increase and a 95 percent confidence interval of 1.193 to 1.629. The statistical significance was robust, with a P value below 0.001, and variance inflation factors indicated that multicollinearity among the covariates did not undermine the model.

The researchers also explored whether bile acid levels could actually discriminate between patients with early kidney disease and those with diabetes alone. Receiver operating characteristic analysis produced an area under the curve of 0.699, a value that reflects modest but real discriminative ability, and an exploratory threshold of 2.80 micromoles per liter derived from the Youden index offered a tentative cutoff for distinguishing stage 1 disease from uncomplicated diabetes. The authors are careful to stress that this threshold is exploratory: given the modest area under the curve and wide confidence intervals, it would need validation in an independent external cohort before any clinical use, and it should not be interpreted as a ready-made diagnostic rule.

Internal validation added a further layer of rigor. Using bootstrap resampling with 1,000 iterations, the team estimated a mean apparent area under the curve of 0.818, with a 95 percent confidence interval of 0.761 to 0.868. After correcting for optimism, the bias-corrected value settled at 0.731, indicating good internal reproducibility of the model while acknowledging that the correction narrows the apparent performance. This kind of bootstrap procedure is increasingly regarded as best practice in clinical prediction research because it tempers the overfitting that can inflate performance estimates when models are evaluated on the same data used to build them. Even so, the authors emphasize that internal validation is no substitute for external confirmation in a genuinely independent population.

What might explain the early bile acid spike? The authors frame their findings as hypothesis-generating, but the biology offers several plausible threads. Bile acids are synthesized in the liver from cholesterol and are normally reabsorbed in the ileum and recycled through enterohepatic circulation. Early kidney injury could perturb this recycling, alter hepatic synthesis through inflammatory or metabolic signaling, or change the expression of bile acid transporters in renal tissue. Signaling through the farnesoid X receptor and TGR5 is known to affect insulin sensitivity and renal microvascular function, so a transient rise in circulating bile acids could be both a marker and a mediator of early nephropathy. The subsequent decline by stage 3 may reflect progressive loss of renal regulatory capacity or exhaustion of the metabolic response, though the cross-sectional design cannot distinguish cause from consequence.

The limitations of the study are clearly acknowledged. As a cross-sectional analysis, it captures a snapshot rather than a trajectory, so it cannot establish whether rising bile acids precede kidney damage or accompany it. The single-center design and the modest discriminative performance of the biomarker both argue for caution. The authors recommend that total bile acid be regarded as a candidate complementary marker, one that might eventually sit alongside the urinary albumin-to-creatinine ratio and estimated glomerular filtration rate rather than replace them, pending prospective validation in external cohorts. Funded by the Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province, the study opens a provocative new line of inquiry into the metabolic choreography of diabetic kidney disease, suggesting that the earliest stage of renal injury carries a distinctive and detectable biochemical signature that current care largely overlooks.

Subject of Research: The non-linear relationship between serum total bile acid levels and early-stage diabetic kidney disease.

Article Title: Total bile acid as an independent indicator for early-stage diabetic kidney disease: a cross-sectional study

Article References: Xu, L., Feng, B., & Yan, X. (2026). Total bile acid as an independent indicator for early-stage diabetic kidney disease: a cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02553-y

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02553-y

Keywords: total bile acid, diabetic kidney disease, type 2 diabetes, biomarker, urinary albumin-to-creatinine ratio, estimated glomerular filtration rate, bile acid metabolism, nephropathy, logistic regression, ROC analysis, endocrinology, kidney disease

PSCI is a notoriously difficult target. Its clinical course is heterogeneous, ranging from subtle deficits in attention and executive function to overt dementia, and its trajectory is highly variable from patient to patient. Current prediction relies largely on conventional clinical variables, neuroimaging findings, and bedside cognitive screening instruments, all of which have well-documented weaknesses during the acute phase. Aphasia, sedation, and neurological fluctuation routinely interfere with early cognitive assessment, while existing clinical prediction models built on variables such as NIHSS score, age, diabetes, atrial fibrillation, and homocysteine, though reported to achieve AUCs between 0.77 and 0.90 in development cohorts, still fail to capture the complex pathophysiology underlying cognitive decline. What clinicians lack is an objective, quantifiable biomarker panel that can stratify risk before symptoms emerge.

The logic behind a metabolic approach is compelling. Ischemic stroke triggers a cascade of disrupted energy metabolism, mitochondrial dysfunction, excitotoxicity, oxidative stress, and neuroinflammation, many aspects of which leave fingerprints in circulating metabolite levels. Stroke also provokes broad peripheral changes, including lipid remodeling, amino acid dysregulation, and perturbation of neurotransmitter-related pathways, which can shape cognitive recovery by affecting neuronal integrity, synaptic plasticity, and cerebrovascular health. Previous work has hinted at the potential: elevated serum ratios of quinolinic acid to kynurenic acid have predicted three-month cognitive outcomes, and the Nor-COAST cohort linked neopterin, kynurenine metabolites, and vitamin B6-related indicators to PSCI development. Choline pathway metabolites and homocysteine have also been independently associated with post-stroke cognitive risk. But most of these studies were targeted, focused on one or a few pathways, and rarely extended to building validated prediction models in the acute window.

The new study, led by Xiangwen Hao and Bianying Feng of Shanghai Fourth People’s Hospital with senior authors Li Tian and Qiu Hong Man, took an untargeted approach. The team enrolled 156 patients admitted within twenty-four hours of symptom onset and, after exclusions for pre-existing cognitive impairment, severe aphasia, psychiatric illness, and other factors, assembled a final cohort of 130. Serum collected on admission was subjected to untargeted liquid chromatography-tandem mass spectrometry using both reversed-phase and HILIC separation on a high-resolution Orbitrap platform, with pooled quality-control samples inserted after every ten study samples to monitor instrument stability. After rigorous preprocessing, including variance-stabilizing normalization and random-forest-based batch correction, 806 serum metabolite features were retained for analysis.

Three months later, patients were assessed with the Telephone Montreal Cognitive Assessment, a validated remote screening tool, and classified as PSCI if they scored below the pre-specified cutoff of 19. The cohort split almost evenly: 64 patients developed cognitive impairment and 66 remained cognitively intact. Comparison of the two groups’ admission serum profiles revealed 51 candidate differential metabolites, twenty upregulated and thirty-one downregulated in those who later declined cognitively. The largest fold change belonged to 5-aminopentanoic acid, a lysine degradation intermediate produced both endogenously and by gut bacteria, which was elevated in PSCI patients and negatively correlated with cognitive scores. Strikingly, key intermediates of caffeine catabolism, including 1,3-dimethyluric acid, theophylline, and 3,7-dimethyluric acid, were markedly reduced in the PSCI group, suggesting altered purine metabolism and potentially disrupted adenosine receptor signaling, a pathway implicated in neuronal excitability, neuroinflammation, and synaptic regulation.

Pathway enrichment analysis mapped these differences onto several interconnected metabolic domains rather than a single dominant mechanism. Bile acid metabolites such as taurocholic acid, cholic acid, and glycochenodeoxycholic acid pointed to bile acid biosynthesis and secretion pathways, increasingly recognized as players in gut-liver-brain communication and systemic inflammation. Lipid features, including docosahexaenoic acid, linoleic acid, and multiple glycerophospholipid species, mapped to unsaturated fatty acid and glycerophospholipid metabolism, and correlated positively with cognitive scores, consistent with the known importance of polyunsaturated fatty acids in membrane structure and synaptic function. Amino acid-related pathways, including arginine and proline metabolism, rounded out the picture. Notably, docosahexaenoic acid and two ether-linked phospholipid species correlated positively with three-month cognitive scores, while the purine metabolite 7-methylguanosine and the indole compound indole-4-carboxaldehyde correlated negatively, tying purine, tryptophan-derived, and lipid metabolic signals directly to cognitive performance.

To move beyond single metabolites, the researchers applied multiscale embedded correlation network analysis across all 806 metabolites spanning thirty biochemical categories. The result was striking: 15,120 metabolite pairs showed significantly different correlation patterns between the two groups. Nearly half of these involved outright reversals, with 3,807 pairs flipping from positive correlations in cognitively intact patients to negative correlations in PSCI patients and 3,671 showing the reverse transition. Others involved newly forged strong correlations or the dissolution of existing ones. The magnitude of this correlation rewiring suggests that patients who later developed cognitive impairment experienced a fundamentally reorganized acute-phase metabolic network, encompassing amino acid handling, lipid metabolism, inflammatory responses, and microbiota-associated features, rather than isolated changes in individual compounds.

The centerpiece of the study is its prediction model. Using bootstrap-LASSO stability selection across 1,000 iterations, with a selection-frequency threshold of 75 percent chosen through sensitivity analysis, the team retained six metabolites: 6-hydroxymellein, 21-deoxycortisol, inosine, 2-hydroxy-3-methylbutyric acid, isoleucyl-arginine, and propylparaben. Under stratified ten-fold cross-validation, this metabolite-only model achieved an AUC of 0.774, with a sensitivity of 0.609 and a specificity of 0.848 at the optimal cutoff. Within the multivariable model, 21-deoxycortisol, an intermediate of adrenal corticosteroid synthesis, showed the strongest positive association with PSCI risk, with an odds ratio of 2.15, hinting at a role for acute hypothalamic-pituitary-adrenal axis activation, a stress response long linked to hippocampal vulnerability and impaired synaptic plasticity. Elevated inosine and the branched-chain amino acid catabolic intermediate 2-hydroxy-3-methylbutyric acid also carried increased odds of impairment, while the dipeptide isoleucyl-arginine and the preservative-derived propylparaben trended toward protective associations.

Perhaps the most provocative result is what the comparison models revealed. A core clinical-only model built from age, sex, education, admission NIHSS score, body mass index, and prior stroke history managed an AUC of just 0.525, barely better than chance in this cohort. Adding the clinical variables to the metabolites did not help either; the combined model reached an AUC of 0.685, still short of the metabolite-only panel. Calibration analysis showed good agreement between predicted and observed risk, with no significant lack of fit, and decision curve analysis indicated the model would deliver net benefit over both treat-all and treat-none strategies across a broad range of threshold probabilities. The authors note that the six predictors span endogenous steroidogenic, purinergic, and amino acid catabolic pathways alongside dietary and xenobiotic exposure markers, underscoring that the acute metabolic risk signature is multidimensional.

The researchers are careful to frame their findings as an early step rather than a finished clinical tool. The cognitive outcome was assessed by telephone screening rather than a full neuropsychological battery, and the model was validated only internally, without an independent external cohort. Untargeted mass spectrometry features would also need conversion into targeted, reproducible, and clinically feasible assays before any bedside deployment. Still, the study demonstrates that the blood of a newly admitted stroke patient already contains readable information about how the brain will fare over the following months. If external validation confirms the six-metabolite panel, emergency departments could one day use a routine admission blood draw to flag high-risk patients for closer cognitive follow-up and early preventive intervention, turning the first hours after a stroke into a window of opportunity for protecting the mind as well as saving it.

Subject of Research: Acute-phase serum metabolomic signatures for early prediction of post-stroke cognitive impairment after ischemic stroke

Article Title: Acute-phase serum metabolomics signatures for predicting post-stroke cognitive impairment after ischemic stroke: a prospective cohort study

Article References: Hao, X., Feng, B., Zhang, X., Li, Y., Chen, J., Zheng, X., Tian, L., & Man, Q. H. (2026). Acute-phase serum metabolomics signatures for predicting post-stroke cognitive impairment after ischemic stroke: a prospective cohort study. Metabolomics, 22(5), Article 148. https://doi.org/10.1007/s11306-026-02521-6

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02521-6

Keywords: post-stroke cognitive impairment, ischemic stroke, metabolomics, biomarkers, serum metabolites, LC-MS/MS, prediction model, bile acid metabolism, caffeine metabolism, docosahexaenoic acid, Bootstrap-LASSO, risk stratification

LCA is a secondary bile acid produced when intestinal microorganisms transform primary bile acids. It participates in bile acid metabolism and can influence cellular signaling, energy balance, and inflammation. At high concentrations, however, LCA has been linked to cholestasis, impaired bile flow, obstruction of bile ducts, hepatocyte injury, and cell death. This apparent contradiction has complicated efforts to explore LCA as a possible therapy. Earlier work had shown that LCA levels rise during caloric restriction, a dietary intervention associated with longer lifespan and improved metabolic health in several organisms.

Caloric restriction is thought to activate a network of metabolic responses that improve glucose handling, mitochondrial function, stress resistance, and tissue maintenance. LCA has been proposed as one of the circulating molecules that may help transmit some of these benefits. In animal studies, the bile acid has been associated with increased muscle NAD+ levels, improved grip strength and endurance in aged mice, and longer lifespan in nematodes and fruit flies. Yet the doses required to produce such effects must be distinguished from the much higher exposures known to damage the liver.

To investigate this dose boundary, a team led by Sheng-Cai Lin of Henan University and Xiamen University first studied obese mice. The animals received LCA in their drinking water at a concentration of 1 gram per liter, producing blood levels of approximately 1 micromole per liter. That exposure was designed to resemble the concentration observed during caloric restriction rather than the substantially higher levels used in toxicology experiments. After four weeks, the mice had lower hepatic triglyceride content, reduced fatty liver, and improved glucose metabolism.

The researchers also examined the molecular pathway behind the response. Liver-specific knockout mice lacking AMPKα did not receive the same metabolic benefits, implicating AMP-activated protein kinase as a central mediator. AMPK is an energy-sensing enzyme that becomes active when cellular energy supplies are limited. Once activated, it can suppress energy-intensive processes such as lipid synthesis while promoting fatty-acid oxidation and other pathways that help restore energy balance. The results indicate that low-dose LCA may improve liver metabolism through this energy-sensing system.

The safety picture changed sharply when the dose was increased. At 250 milligrams per kilogram per day, hepatic LCA concentrations reached about 14 micromoles per liter, and the mice developed clear signs of liver injury. This contrast provided direct evidence for a dose-dependent safety window: concentrations near those associated with caloric restriction appeared beneficial, while substantially higher exposure became toxic. The distinction is particularly important because bile acids can accumulate in the liver and exert effects that are not predicted simply by the administered dose.

The team next tested LCA in cynomolgus macaques with fatty liver. Translating doses from rodents to primates proved more complicated than expected. The monkeys rejected the formulation used in the mouse experiments, so the researchers developed a phospholipid-coated preparation suspended in fish oil. When they administered a mouse-equivalent dose calculated by body-surface-area conversion—9.6 milligrams per kilogram—the animals’ serum LCA concentrations rose above 6 micromoles per liter. Within one week, alanine aminotransferase and aspartate aminotransferase, enzymes commonly used to detect liver injury, increased significantly.

That result demonstrated why standard interspecies dose conversion can be unreliable for compounds whose absorption, metabolism, and circulation differ between animals. The researchers therefore conducted a dose-titration study in the macaques and identified two lower regimens: 0.25 milligrams per kilogram and 0.5 milligrams per kilogram, administered twice daily. These schedules maintained steady-state blood concentrations of approximately 0.8 to 1 micromole per liter, close to the target range observed in the mouse experiments, without producing biochemical evidence of liver damage.

After 13 weeks, macaques receiving either low-dose regimen showed significant histological improvement in hepatic steatosis, the abnormal accumulation of fat inside liver cells. Their body weight, blood lipids, and glucose levels remained stable, while ALT, AST, creatinine, and blood counts showed no treatment-related abnormalities. The findings do not establish that LCA is ready for human use, and the study involved early-stage fatty liver rather than advanced disease with severe hyperglycemia or hypertriglyceridemia. Longer studies will be needed to assess tissue distribution, sex-related differences, chronic toxicity, and responses in more advanced models. Nevertheless, the work provides the first reported evidence in a non-human primate that a carefully controlled, caloric-restriction-like concentration of LCA may alleviate fatty liver through hepatic AMPK activation without detectable toxicity.

Article Title: Lithocholic acid alleviates fatty liver in mice and non-human primate macaques

News Publication Date: 23-Jul-2026

Web References: https://doi.org/10.1093/lifemeta/loag023

References: Life Metabolism, DOI: 10.1093/lifemeta/loag023

Image Credits: Higher Education Press

Keywords: lithocholic acid, LCA, fatty liver, metabolic dysfunction-associated steatotic liver disease, caloric restriction, AMPK, bile acids, cynomolgus macaques, liver metabolism, hepatotoxicity